Lung (Non-Small Cell) Cancer: CTSU E1505 (Hematology Oncology Associates)

CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)

Objective

This research is being done because even with the most aggressive after surgery treatment with chemotherapy, many people still have the lung cancer recur (come back). 

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. The study will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on patients with lung cancer to see which is better at preventing the cancer from coming back. The drug bevacizumab has not yet been Food and Drug Administration (FDA) approved for treatment of lung cancer that has been removed. It has been FDA approved for lung cancer that has come back or spread beyond the lung.



Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Sponsor(s)
Cancer Trials Support Unit
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email